Medical Research
(H125)
IRS Verified
DX Registered
990 on File
CITIZENS UNITED FOR RESEARCH IN EPILEPSY
Financial strength (30%)
68/100
Reliability (20%)
55/100
Effectiveness (25%)
85/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2025
$5.0M
Total Revenue
$5.5M
Total Expenses
$6.7M
Net Assets
20
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
81.3%
Fundraising Efficiency
976.8%
Operating Reserve
14.53x
Liability-to-Asset
35.7%
Revenue Diversification
99.0%
Executive Compensation
$380K
Compared with Peers
FY 2025
Compared with 132 similar organizations
(United States, Medical Research, $1M–$10M in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
81.3% | 83.0% |
P10P90
|
Below median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
5.9% | 9.9% |
P10P90
|
Top quarter |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
12.8% | 2.6% |
P10P90
|
Bottom quarter |
|
Fundraising efficiency
Fundraising expenses / gross fundraising income
· lower is better
|
976.8% | 110.6% |
P10P90
|
Bottom quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
14.5 mo | 14.4 mo |
P10P90
|
Above median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
35.7% | 13.2% |
P10P90
|
Bottom quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
99.0% | 90.0% |
P10P90
|
Bottom quarter |
|
Revenue growth
Year over year revenue growth
|
-17.5% | 7.4% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
-10.8% | 3.0% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
-10.8% | 4.8% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $5.0M | $5.5M | $6.7M | 81.3% | 20 |
| 2024 | $6.1M | $6.2M | $7.0M | 83.6% | 22 |
| 2023 | $6.2M | $6.0M | $7.0M | 84.4% | 19 |
| 2022 | $6.2M | $5.8M | $6.2M | 86.4% | 19 |
| 2021 | $6.0M | $5.8M | N/A | — | 16 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.